Journal
ONCOIMMUNOLOGY
Volume 8, Issue 11, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2019.1655363
Keywords
Oncolytic virotherapy; neoadjuvant therapy; breast cancer; triple-negative breast cancer; immune checkpoint blockade
Categories
Funding
- Institut du cancer de Montreal
Ask authors/readers for more resources
Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, controls metastases and sensitizes tumors to immune checkpoint inhibitors (ICIs).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available